Osteoarthritis and Bone Disorders News

The severity and cost of work-related musculoskeletal disorders among Ohio construction workers from 2007 to 2017 increased with age, peaking in those aged 55 to 64 years, according to data published in Morbidity and Mortality Weekly Report.

Two dosing regimens of tanezumab yielded comparable outcomes in pain and function as NSAIDs across a number of osteoarthritis patient subgroups, according to a speaker at the 2021 OARSI World Congress virtual meeting.

This year’s iteration of the Great Debate at the OARSI 2021 World Congress centered on the role of nerves in pain, functionality and pathogenesis of osteoarthritis.

The COVID-19 pandemic forced the rheumatology community to adopt a number of telehealth and digital approaches in patient care, according to a speaker at the 2021 OARSI World Congress virtual meeting.

Intra-articular injections of mesenchymal stem cells into the synovium may yield expression of a number of genes that inhibit progression of osteoarthritis, according to a speaker at the 2021 OARSI World Congress virtual meeting.

Pain in obese individuals with osteoarthritis is caused by biomechanical and inflammatory processes and may involve depression, according to a speaker at the 2021 OARSI World Congress.

Understanding the complex associations between pain, function and structural factors in the joints may allow clinicians to use intraarticular injections more effectively in osteoarthritis, according to a speaker at the 2021 OARSI World Congress.

The Osteoarthritis Research Society International continues to thrive despite setbacks presented by the pandemic, according to the organization’s president, Ali Mobasheri, DPhil (Oxon), who opened the 2021 OARSI World Congress.

Progress toward effective drug therapies is often marked with failure; yet even among a host of difficult-to-treat arthritis conditions, osteoarthritis has received a disproportionate share of therapeutic setbacks and disappointing clinical trials.

Patients with both X-linked hypophosphatemia and tumor-induced osteomalacia can benefit from phosphorus replacement therapy, according to two presentations at the United Rheumatology Spring Virtual conference.